We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

73 hedge funds and large institutions have $1.81B invested in Verve Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 30

6% more funds holding

Funds holding: 69 → 73 (+4)

1.03% less ownership

Funds ownership: 81.71% → 80.68% (-1%)

19% less capital invested

Capital invested by funds: $2.25B → $1.81B (-$437M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+4
Holders Change %
+5.8%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
34
Increased
16
Reduced
13
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$71.6M
2
AIM
ARK Investment Management
Florida
+$42.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$37M
4
BlackRock
BlackRock
New York
+$24.4M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.3M
2
Millennium Management
Millennium Management
New York
-$24.7M
3
LGM
Logos Global Management
California
-$18.5M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$14.9M
5
NHAS
Novo Holdings A/S
Denmark
-$11.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
26
Nicholas Investment Partners
California
$6.22M +$7.78M +132,300 New
Charles Schwab
27
Charles Schwab
California
$4.83M +$6.05M +102,810 New
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$4.77M +$2.57M +43,647 +75%
EC
29
EcoR1 Capital
California
$4.7M – – –
Sumitomo Mitsui Trust Group
30
Sumitomo Mitsui Trust Group
Japan
$3.69M +$4.61M +78,421 New
NAMA
31
Nikko Asset Management Americas
New York
$3.61M +$4.61M +78,421 New
N
32
Nuveen
North Carolina
$2.82M +$3.53M +59,997 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.64M +$3.31M +56,258 New
Goldman Sachs
34
Goldman Sachs
New York
$1.98M -$4.49M -76,359 -64%
Ameriprise
35
Ameriprise
Minnesota
$1.34M +$137K +2,326 +9%
DGM
36
Darwin Global Management
Jersey
$1.29M -$4.45M -75,616 -73%
HS
37
HighVista Strategies
Massachusetts
$883K +$1.1M +18,782 New
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$829K +$1.04M +17,640 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$769K +$962K +16,359 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$752K +$575K +9,781 +157%
CCM
41
CAAS Capital Management
New York
$705K – – –
GCM
42
Ghisallo Capital Management
Massachusetts
$705K +$294K +5,000 +50%
ABG
43
Ally Bridge Group
New York
$705K +$882K +15,000 New
MFS
44
Mirabella Financial Services
United Kingdom
$673K +$842K +14,320 New
CCM
45
Cinctive Capital Management
New York
$564K +$706K +12,000 New
Deutsche Bank
46
Deutsche Bank
Germany
$444K +$557K +9,461 New
CIBC World Market
47
CIBC World Market
Ontario, Canada
$434K +$544K +9,239 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$416K +$104K +1,760 +25%
AIG
49
American International Group
New York
$406K +$509K +8,648 New
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$401K +$502K +8,538 New
1
2
3 4 5

VERV Hedge Fund Activity: Q3 2021 in Review

73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2021, worth a combined $1.81B — down 19% from $2.25B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new VERV positions and 30 closed out — a net gain of 4 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $71.6M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $41.3M sold.

  • 73 institutional investors held Verve Therapeutics (VERV) as of Q3 2021, up from 69 in Q2 2021.
  • Funds reported $1.81B of Verve Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
  • 34 funds opened new Verve Therapeutics positions in Q3 2021 and 30 closed out, a net change of +4 holders.
  • The largest Verve Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $71.6M added.
  • The largest Verve Therapeutics seller in Q3 2021 was T. Rowe Price Associates, an estimated $41.3M sold.

Based on aggregated 13F filings for Q3 2021.